Immunotherapy is a new opportunity for managing patients with “thin” endometrium in cycles of transfer of thawed embryos

The trend of recent decades has been the search for therapeutic effects on the so-called “thin” endometrium. However, to date there is no optimal management scheme for patients with “thin” endometrium in assisted reproductive technology programs. Aim: to evaluate the effectiveness of using recombinant IL-2 before cryotransfer in women of late reproductive age with “thin” endometrium and repeated implantation failure after transfer of good quality embryos. The study included 63 patients of late reproductive age with “thin” endometrium. The first group consisted of 25 patients of late reproductive age with a history of unsuccessful in vitro fertilization programs with good quality embryos. Cryotransfer to the patients of the first group was carried out in a modified natural cycle. The second group included 38 women of late reproductive age with a history of unsuccessful in vitro fertilization programs with good quality embryos. Cryotransfer for women of the second group was carried out in a cycle with hormone replacement therapy. Recombinant IL-2 in the cycle before cryotransfer were prescribed to all women. In both groups, implantation, clinical pregnancy, and live birth rates following administration of recombinant IL-2 were valuable. In both groups, the implantation rate, clinical pregnancy rate and live birth rate were assessed after administration of recombinant IL-2. Statistical data processing was performed using application software package Statistica 6.0 (StatSoft, Ink. 1994-2001), adapted for biomedical research. p 0.05 was considered significant. After recombinant IL-2 treatment of patients with infertility and thin endometrium, endometrial thickness increases statistically significantly in the first two menstrual cycles after treatment, so transfer of thawed embryos should be planned in the first two menstrual cycles after immunotherapy. In order to increase the thickness of the endometrium during cryotransfer in a modified natural cycle, as well as in a cycle with replacement hormone therapy, recombinant IL-2 can be used in women with “thin” endometrium with repeated unsuccessful implantation attempts when transferring good quality embryos. Cryotransfer should be performed in the first two menstrual cycles after immunotherapy.